Endo Pharmaceuticals Reports First Quarter 2009 Financial Results
LIDODERM(R) : For the quarter ended March 31, 2009, net sales of lidoderm
decreased 5% to $171.6 million compared with $180.5 million in the same period a year ago. Prescription volume for lidoderm
decreased 2% in the first quarter of 2009 versus the comparable 2008 period...
Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results
...92 in 2007.
Selected Product Review
(R) : For the quarter ended December 31, 2008, net sales of lidoderm
decreased 2% to $205.4 million compared with $208....he same period a year ago. Prescription volume for lidoderm
increased 1% in the fourth quarter of 2008 versus ...
Lidoderm for pain removal in Osteoarthritis
...is in one or both knees. //
The treatment tested was providing one full lidoderm
patch in the front of the knee and one third patch on the back of the affec... only to be applied on intact skin. The FDA approves up to three patches of lidoderm
applied to a total of 12 hrs in a 24 hrs period. Its efficacy in pain remov...
Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results
...nues to perform well, with a solid performance for lidoderm
and strong growth in sales of Opana, Voltaren Gel ...Selected Product Review
((R)) : In September, Endo will celebrate the ... For the quarter ended June 30, 2009, net sales of lidoderm
increased 6 percent to $195.5 million compared wit...